Overview / Abstract: |
This educational program is designed for infectious disease pharmacists interested in new therapies and clinical trials in the treatment of CDI. Dr. Paul Feuerstadt and Dr. Kevin Garey discuss community and healthcare-associated infections, recent updates to guidelines, and evidence-based selection of antimicrobial therapy for the treatment of initial infection and prevention of recurrence. What happens if the patient returns with recurrence? Watch to find out as the faculty discuss a patient case highlighting the risks of recurrence and selection of therapy. |
Expiration |
Oct 29, 2022 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME |
Format |
Online, Webinar / Webcast / Video |
Credits / Hours |
1.0 |
Accreditation |
ACPE |
Is This Activity Certified for "Live" Credit? |
YES |
Presenters / Authors / Faculty |
Paul Feuerstadt, MD, FACG, AGAF Kevin W. Garey, PharmD, MS |
Activity Specialities / Related Topics |
Gastroenterology / GI, Infectious Disease |
Sponsors / Supporters / Grant Providers |
Sponsored by the Academy for Continued Healthcare Learning (ACHL). Supported by an educational grant from Merck & Co., Inc. |
Keywords / Search Terms |
ACHL C. difficile, CME/CE/CPE, MAD-ID, Dr. Feuerstadt, Dr. Garey, recurrent, infections, infectious disease, physician, pharmacists, microbiota restoration therapy, bacterial infections, gram-negative, clinical cases, fidaxomicin, vancomycin, IDSA/SHEA, ACG Free CE CME Live CE CME |